IBRO Neuroscience Reports, published by Elsevier, is a pivotal open-access journal dedicated to advancing the field of neuroscience. With its ISSN 2667-2421, the journal serves as a vital platform for researchers, professionals, and students alike, showcasing innovative research and interdisciplinary studies that span various aspects of neuroscience. Since its inception in 2021, and with a planned convergence through 2024, the journal has quickly established itself within the academic community, currently holding a Q3 category ranking in the field of Neuroscience (miscellaneous) and a Scopus rank of #77 among 113 in General Neuroscience, reflecting its ongoing commitment to quality and relevance. The accessibility of research articles ensures that critical findings are widely disseminated, fostering collaboration and dialogue within the neuroscientific community. Researchers and professionals are encouraged to contribute to this dynamic journal, reinforcing its role in shaping the future of neuroscience research.

Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

Purinergic Signalling, published by Springer, is a pivotal academic journal dedicated to the exploration of purinergic signaling pathways and their implications in various biological processes. Since its inception in 2004, the journal has made significant contributions to the fields of Cell Biology, Cellular and Molecular Neuroscience, and Molecular Biology, consistently ranking in the Q3 category in recent assessments. With a strong focus on the molecular mechanisms of purines and their roles in physiology and pathology, Purinergic Signalling serves as an essential resource for researchers and professionals seeking to understand the complexity of cellular communication. Although it does not offer open access, the journal ensures a broad dissemination of high-quality research findings, making it a vital tool for academic advancement in the fields of neuroscience and molecular biology. Its commitment to scholarly excellence is reflected in its Scopus rankings, where it is competitively positioned within its categories. As we approach its 20th anniversary in 2024, Purinergic Signalling continues to inspire and inform cutting-edge research in the dynamic landscape of life sciences.

Neuropeptides is a prestigious, peer-reviewed journal published by Elsevier, focusing on the critical role of neuropeptides in various biological processes and their implications in cellular and molecular neuroscience, endocrinology, and neurology. With an impact factor reflecting its influence in the field and a diverse audience ranging from researchers to healthcare professionals, the journal serves as an essential platform for the dissemination of groundbreaking research from 1980 to 2024. Adhering to high academic standards, Neuropeptides holds a Q3 ranking in Cellular and Molecular Neuroscience and Endocrine and Autonomic Systems, alongside a solid Q2 ranking in both Endocrinology and Neurology. This positions the journal at the forefront of its disciplines, contributing valuable insights into the understanding of neuropeptide functions in health and disease. By not operating as an Open Access journal, it ensures sustainability in the publishing process while upholding rigorous review standards. Researchers, professionals, and students are encouraged to engage with the findings published in this journal, which plays a vital role in advancing knowledge and fostering collaboration within the neuroscientific community.

Journal of Neuroinflammation is a premier open-access journal published by BMC that has been at the forefront of research in the field since its inception in 2004. With a strong focus on the intricate interplay between the nervous system and immune responses, this journal aims to create a forum for the dissemination of high-quality research that informs our understanding of neuroinflammation and its implications in neurological disorders. Positioned in the top quartile across multiple categories including Cellular and Molecular Neuroscience, Immunology, and Neurology, the journal ranks impressively within the Scopus database, ensuring visibility to the global research community. The Journal of Neuroinflammation provides a vital platform for researchers and professionals to share groundbreaking findings, methodologies, and reviews that advance science and foster collaboration. With its commitment to open access, the journal ensures that its content is accessible to a broad audience, enhancing the dissemination of knowledge in this critical field of study.

ACTA NEUROBIOLOGIAE EXPERIMENTALIS, an esteemed journal published by the Nencki Institute of Experimental Biology in Poland, has been a pivotal platform for the dissemination of research in the fields of medicine and neuroscience since its inception in 1970. With an ISSN of 0065-1400 and an E-ISSN of 1689-0035, this journal has consistently aimed to contribute to the understanding of neurobiological phenomena, cementing its status within the academic community. Despite its current categorization in the Q3 and Q4 quartiles for Medicine and Neuroscience respectively, ACTA NEUROBIOLOGIAE EXPERIMENTALIS continues to uphold rigorous scientific standards, providing an invaluable resource for researchers, professionals, and students alike. As an essential scholarly outlet, it encourages the exploration of groundbreaking findings and clinical applications in neurobiology, making it an attractive choice for those eager to advance their understanding of this intricate field.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.